How to Analyse Pharmaceutical Stocks in India
To analyse pharmaceutical stocks in India, first identify how each company actually earns: domestic branded formulations, US generics, complex products, active pharmaceutical ingredients, contract manufacturing, consumer health or specialty medicines. Then connect regulatory compliance, R&D productivity, launch economics, price controls, working capital and cash flow to a normalised earnings base. Reported profit without product and geography context is not enough.
Pharmaceutical Companies Use Different Economic Models
| Business Model | Revenue Driver | Core KPI | Main Risk |
|---|---|---|---|
| India branded formulations | Prescription demand, field-force productivity and brand strength | Therapy growth, volume, price, new products and market share | Price controls, doctor concentration and weak launch productivity |
| US generics | Approvals, launches, market share and competitive intensity | Filing pipeline, approvals, price erosion and plant compliance | Regulatory action, litigation and rapid commoditisation |
| Complex generics or specialty | Technically difficult products with fewer competitors | Addressable market, approval probability, gross margin and persistence | Clinical, legal, regulatory and reimbursement uncertainty |
| API and intermediates | Customer contracts, process chemistry and capacity utilisation | Volume, realisation, yield, utilisation and customer concentration | China-linked inputs, cycle pricing and environmental compliance |
| CDMO or custom synthesis | Long development relationships and commercial supply | Project progression, molecule mix, utilisation and client retention | Concentration, project failure and lumpy scale-up |
| Consumer health | Brands, distribution and repeat purchase | Volume, advertising, distribution and gross margin | Brand fatigue, claims regulation and channel competition |
A high multiple may be rational for a durable specialty or CDMO franchise and dangerous for a commoditised generic portfolio. Do not compare companies before separating their economic engines.
Do Not Capitalise a One-Time Product Opportunity Forever
A temporary exclusivity, shortage, litigation settlement or first-to-file launch can create exceptional profit. That profit may disappear as competitors enter. Build a bridge from reported EBITDA to recurring EBITDA by removing unusual product contribution, remediation costs, milestone income, settlements and currency effects.
Rule: value repeatable product economics, not the peak quarter of a temporary opportunity.
1. Map Revenue by Geography, Therapy and Product Type
Start with a revenue map. Domestic chronic therapies can have different growth and retention from acute therapies. US generic revenue may be sensitive to approvals and price erosion. Europe and emerging markets can depend on tenders, local partners and currency. API revenue behaves differently from finished formulations.
Record the percentage of sales, growth, margin characteristics and regulatory exposure for every important segment. A company described as diversified can still depend heavily on one geography, customer, plant or molecule.
2. Analyse Domestic Branded Formulations Properly
For the India business, break growth into volume, price and new products. Compare the company with the therapy market rather than the overall market. A cardiology-heavy portfolio should be judged against cardiology growth; a respiratory portfolio should be judged against respiratory demand and competitive launches.
Underlying Prescription Demand
Check whether growth comes from more prescriptions and patients rather than only permitted price increases.
Chronic versus Acute
Chronic therapies can support repeat demand, but competition and doctor relationships still matter.
Field-Force Productivity
Sales per representative, doctor coverage and launch productivity reveal whether commercial spending creates durable revenue.
New Product Contribution
Track launches for several years. A long list of launches is not useful when few become meaningful brands.
3. Treat Regulatory Compliance as a Cash-Flow Variable
Manufacturing compliance affects supply continuity, approvals, remediation spending and management attention. Review inspection outcomes, warning letters, import alerts, product recalls and commitments made to regulators. A plant issue can delay launches or move production to a more expensive site.
Do not reduce compliance analysis to a binary label. Ask which products use the facility, what revenue depends on it, whether alternate capacity exists, how long remediation may take and how much capital or operating expense is required.
4. Measure R&D Productivity, Not R&D Percentage Alone
R&D-to-sales is an input, not an outcome. Build a multi-year schedule of filings, approvals, launches, discontinued projects and commercial contribution. For specialty or biosimilar projects, probability-weight the pipeline and recognise that clinical, regulatory and commercial risks can persist after technical development.
A productive research organisation converts spending into differentiated products, approvals and cash. An unproductive one accumulates filings that enter crowded markets or never recover development cost.
5. Understand US Generics Price Erosion
US generic economics depend on competitor count, channel concentration, customer contracts, supply reliability and legal status. Separate base-business erosion from new launches. A company can report stable revenue while replacing a shrinking base with increasingly expensive launches.
Study gross margin and cash contribution, not only market size. A large addressable market can become unattractive after price cuts, rebates, litigation expense and working capital.
6. Evaluate APIs and CDMO Businesses with Project Economics
For API companies, examine process yield, backward integration, customer audits, capacity utilisation, environmental approvals and dependence on a few molecules. For CDMO businesses, follow projects from development to validation and commercial supply. The pipeline should be translated into probability-adjusted revenue rather than treated as guaranteed.
Customer concentration is not automatically bad when relationships are long, switching costs are high and project visibility is strong. It becomes dangerous when one molecule or client drives capex without contractual or technical protection.
7. Track Gross Margin, Working Capital and Cash Conversion Together
Gross margin can move because of product mix, temporary opportunities, currency, input cost, freight and plant utilisation. Compare margin with inventory and receivables. Inventory may rise ahead of launches or because demand is weak; receivables may rise in tender or emerging-market businesses.
Calculate operating cash flow before and after remediation, litigation and acquisition payments. Strong accounting profit with persistent inventory build and weak cash collection deserves a lower-quality assessment.
8. Review Acquisitions and Intangible Assets
Pharma companies frequently buy brands, portfolios, manufacturing assets or specialty platforms. Separate acquired growth from organic growth. Test whether the purchase improves distribution, therapy leadership, technology or product access, and whether the acquired cash flow justifies goodwill and debt.
Watch impairment history, contingent consideration, milestone payments and capitalised development. Adjust return on capital for economically necessary intangibles rather than ignoring them.
9. Build a Regulatory and Product-Risk Checklist
- Which facilities support the most valuable products and markets?
- Are approvals dependent on unresolved inspections, litigation or partner action?
- How much revenue comes from price-controlled products or tender channels?
- Are launches protected by complexity, supply reliability or intellectual property?
- What percentage of R&D has produced commercially meaningful launches?
- Could a single recall, customer loss or competitor entry alter the earnings base?
10. Value Normalised Pharmaceutical Earnings
PE, EV/EBITDA, free-cash-flow yield and sum-of-the-parts analysis are useful after normalisation. Remove temporary product profit and include recurring compliance, R&D and maintenance capex. Value specialty pipelines using probability-adjusted cash flow rather than headline market size.
A premium can be justified by regulatory reliability, differentiated products, strong domestic brands, productive R&D and net cash. It should not be justified by a vague pipeline, temporary shortage revenue or acquisition-led growth alone.
A 55-Minute Pharma Research Workflow
Minutes 1–8: Build the business-model map
Split revenue and profit by geography, therapy, product type and manufacturing model.
Minutes 9–17: Review growth quality
Separate volume, price, launches, acquisitions, currency and temporary opportunities.
Minutes 18–27: Audit regulatory exposure
Map facilities to products and markets; review inspections, remediation and alternate capacity.
Minutes 28–36: Test R&D productivity
Compare historic spending with approvals, launches, commercial contribution and failures.
Minutes 37–45: Inspect cash and balance sheet
Review inventory, receivables, operating cash flow, acquisitions, goodwill, debt and contingencies.
Minutes 46–55: Normalise and value
Remove exceptional products and costs, compare close peers and record the assumptions that must hold.
Related Bull Run Research
Primary Official Sources
Disclaimer
This article is for educational and informational purposes only. It is not investment advice, medical advice, a research report or a stock recommendation. Product approvals, inspection status, prices, litigation, clinical results and market conditions can change. Verify material information through company filings, CDSCO, NPPA and official exchange disclosures. Bull Run is not a SEBI-registered Research Analyst or Investment Adviser.
Analyse the Product Portfolio Before the Multiple
Start with Bull Run's pharmaceutical sector page, open relevant stock profiles and use the comparison tool. The strongest pharma company converts compliance, science and commercial execution into repeatable cash after the full cost of R&D, remediation and capital.